NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Diagnostics & Research · USD

GeneDx Holdings Corp. (WGS) Stock Analysis

GeneDx Holdings Corp. (WGS) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

WGS

$85.99

−$1.40 (−1.60%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare WGS with… →

WGS Key Statistics

As of Sep 4, 2026
Trading
Open
$87.78
Previous Close
$87.39
Day's Range
84.16–87.99
52-Week Range
32.21–170.87
Volume
304.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.01
Valuation
Market Cap
$2.56B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
73.57
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
5.64
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.58
Financials (FY)
Revenue (FY)
$427.54M+39.97%
Net Income (FY)
−$21.02M
Profit marginThe share of revenue left as profit after all costs and taxes.
−23.41%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
29.82M
1-Year Return
−33.99%
Dividend and dates
Earnings Date
October 27, 2026estimated
Avg Volume
797.82K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

WGS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−33.88%
2025+69.22%
2024+2694.91%
2023−68.43%
2022−94.08%
2021−59.60%
2020 (partial year)+12.65%

As of September 4, 2026.

WGS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$427.54M−$21.02M−4.9%
2024$305.45M−$52.29M−17.1%
2023$202.57M−$175.77M−86.8%
2022$234.69M−$548.98M−233.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$427.54M$298.17M−$13.08M−$21.02M−4.9%
2024$305.45M$194.40M−$23.21M−$52.29M−17.1%
2023$202.57M$90.01M−$170.19M−$175.77M−86.8%
2022$234.69M−$26.75M−$457.51M−$548.98M−233.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

WGS Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricWGSDiagnostics & Research medianvs median
P/S ratio5.644.9913% above
Profit margin−23.41%0.00%23.4 pts below

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 14 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values GeneDx Holdings Corp. (WGS) at $2.56B. The company sits in the Healthcare sector, in the Diagnostics & Research industry. The company reports 1,300 employees.

The most recent close on file for WGS is $85.99, dated September 4, 2026. That is −$1.40 (−1.60%) against the previous close. The 52-week range on file runs from $32.21 to $170.87. The latest close sits 166.97% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $427.54M. That is +39.97% against the prior fiscal year, when revenue was $305.45M. The same year closed with a net loss of $21.02M. The reported profit margin is −23.41%. That is 23.4 percentage points below the Diagnostics & Research median of 0%. Earnings per share on a trailing basis come to −3.58.

Across the 4 fiscal years on file, revenue moves from $234.69M in 2022 to $427.54M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 73.57. Measured against sales, the shares trade at 5.64 times revenue. On price-to-sales that is 13.08% above the Diagnostics & Research median of 4.99. 49 Diagnostics & Research companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned −33.99%. Measured over 5 years, that is −23.58% a year compounded. Beta against the wider market is reported at 2.01. Annualized volatility over the trailing 5 years is 109.73%.

Growth & Income

The record shows no dividend for WGS.

The strongest complete calendar year on file is 2024 at +2,694.91%; the weakest is 2022 at −94.08%. Of the 5 complete calendar years on file, 2 finished higher. So far in 2026 the price is −33.88%.

Peer Comparison

GeneDx Holdings Corp. (WGS) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
GeneDx Holdings Corp. WGS $2.56B —
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. GeneDx Holdings Corp. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About GeneDx Holdings Corp.

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.

Visit website →